20:40 , Jan 5, 2018 |  BC Week In Review  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's close...
23:19 , Dec 26, 2017 |  BC Extra  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said Tuesday it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's...
07:00 , Jun 17, 2013 |  BioCentury  |  Strategy

Externalizing Astellas

With a stocked late-stage pipeline, Astellas Pharma Inc. has decided to restructure its R&D and give more attention to finding early stage programs by looking outside. The Japanese pharma will eliminate much of its bricks-and-mortar...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Clinical News

AZD2820: Development discontinued

Palatin said partner AstraZeneca discontinued AZD2820. In June, AstraZeneca halted a Phase I trial after it could not exclude that a serious adverse event was linked to the compound (see BioCentury, June 25). Despite the...
00:33 , Sep 8, 2012 |  BC Extra  |  Company News

AZN discontinues AZD2820

Palatin Technologies Inc. (NYSE:PTN) said partner AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued AZD2820, a melanocortin (MC) receptor partial agonist that was in development for obesity. In June, AstraZeneca halted a Phase I trial after it could...
07:00 , Jul 9, 2012 |  BioCentury  |  Strategy

Belviq breaks through

Arena Pharmaceuticals Inc. and partner Eisai Pharmaceuticals Co. Ltd. will have a fine line to walk as they market Belviq lorcaserin for obesity. They want to improve patient compliance, which historically has not been good...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Clinical News

AZD2820: Phase I halted

Palatin said partner AstraZeneca halted a single-blind, placebo-controlled, Phase I trial evaluating AZD2820 in obese men following a serious adverse event in 1 patient. Palatin said the patient may have had an allergic reaction following...
00:47 , Jun 20, 2012 |  BC Extra  |  Clinical News

Palatin falls as obesity trial halted

Palatin Technologies Inc. (NYSE-A:PTN) fell $0.09 (17%) to $0.43 on Tuesday after partner AstraZeneca plc (LSE:AZN; NYSE:AZN) halted a Phase I trial of AZD2820 in obese men following a serious adverse event in one patient....
07:00 , Jun 11, 2012 |  BC Week In Review  |  Company News

Drais, Seldar, Astellas deal

Astellas and Drais partnered to form virtual company - Seldar Pharma Inc. - that will develop and commercialize Astellas' ASP7147 for irritable bowel syndrome with diarrhea. Seldar, which will be managed by Drais' executive...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Company News

Drais, Telsar Pharmaceuticals Inc., Astellas deal

Astellas and Drais partnered to form virtual company Telsar to develop and commercialize Astellas' ulcerative colitis (UC) compound ASP3291. Telsar will be managed by Drais' executive team. Telsar will own all rights and assets...